XNYS · Healthcare · Medical Instruments & Supplies
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | 0.12 | 0.13 | +8.33% | $320.4M | ✅ Beat | -1.89% | -0.22% | — |
| 2026-03-04 | Q4 2025 | 0.20 | 0.21 | +5.00% | $403.4M | ✅ Beat | +12.83% | -13.09% | -21.54% |
| 2025-11-06 |
| Q3 2025 |
| 0.14 |
| 0.16 |
| +14.29% |
| $354.5M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-05 | Q2 2025 | 0.11 | 0.13 | +18.18% | $317.5M | ✅ Beat | -0.31% | -5.46% | -0.22% |
| 2025-03-06 | Q4 2024 | 0.19 | 0.20 | +5.26% | $352.8M | ✅ Beat | +4.15% | -4.20% | -7.58% |
| 2024-11-05 | Q3 2024 | 0.14 | 0.13 | -7.14% | $305.4M | ❌ Miss | +0.22% | -7.78% | -10.49% |
| 2024-08-06 | Q2 2024 | 0.11 | 0.10 | -9.09% | $279.5M | ❌ Miss | -1.26% | +4.18% | +7.65% |
| 2024-05-09 | Q1 2024 | 0.12 | 0.09 | -25.00% | $256.3M | ❌ Miss | +3.41% | -0.90% | -12.32% |
Showing last 8 quarters.